Your AI-Trained Oncology Knowledge Connection!

Jaclyn F. Hechtman, MD

home / authors / jaclyn-f-hechtman-md

Articles

Metastatic CRC: Unmet Needs and Future Directions in Care

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

January 4th 2023

Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.

FRESCO-2 Trial: Role of Fruquitinib in Refractory Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

January 4th 2023

Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.

Role of Immunotherapies in Microsatellite Stable Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

December 28th 2022

Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.

Updates in the Management of KRASG12C-Mutated Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

December 28th 2022

Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.

Emerging Targets in the Treatment of Metastatic Colorectal Cancer

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

December 21st 2022

A panel of expert oncologists discusses advances in the treatment of BRAFV600E metastatic colorectal cancer and also reviews novel targets being investigated in the setting of metastatic colorectal cancer.

Metastatic CRC: Selecting the Appropriate HER2-Directed Therapy

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

December 21st 2022

Experts offer insights on the appropriate treatment for patients with HER2-positive metastatic colorectal cancer.

MOUNTAINEER Study: Tucatinib in Patients With HER2-Positive Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

December 14th 2022

Expert panelists review data from the MOUNTAINEER study, which tested tucatinib alone or in combination with trastuzumab in patients with metastatic colorectal cancer.

DESTINY-CRC01: Role of Trastuzumab Deruxtecan in HER2-Positive Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

December 14th 2022

Shared perspective on the use of trastuzumab deruxtecan in HER2+ metastatic colorectal cancer following results from the DESTINY-CRC01 trial.

Overview of HER2-Positive Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

December 7th 2022

A panel of expert oncologists consider how HER2 expression can positively impact the selection of targeted therapies for patients with metastatic colorectal cancer.

PARADIGM Trial: Panitumumab in RAS Wild-Type and Left-Sided Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

December 7th 2022

Expert perspectives on the PARADIGM study, which highlighted the role of panitumumab in combination with frontline chemotherapy in patients with left-sided, RAS wild-type metastatic colorectal cancer.

Role of ctDNA and MRD in Identifying and Managing Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

November 30th 2022

Shared insight on the optimal use of circulating tumor DNA and minimal residual disease in the identification and management of metastatic colorectal cancer.

Molecular Testing in Metastatic CRC

Cathy Eng, MD;Tanios S. Bekaii-Saab, MD, FACP;Kristen K. Ciombor, MD, MSCI;Jaclyn F. Hechtman, MD

November 30th 2022

Opening their discussion on metastatic colorectal cancer management, expert panelists reflect on the molecular testing paradigm in the setting of diagnosis and workup.